Title
Category
Credits
Event date
Cost
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.25 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Radiation therapy is an integral part of cancer treatment across many disease sites, but the locoregional control benefits must be weighed against the potential toxicities. During this webinar, Kevin Pearlstein, MD, will review the role of radiation in cancer care including basic radiobiologic principles, logistics, and toxicities. He will discuss several recent studies examining the omission of radiation for different solid malignancies and review strategies to identify patients who will benefit the most from radiation.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.25 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Michael Galgano, MD, FAANS, will focus on differentiating the various types of spinal tumors, ranging from metastases, to primary vertebral column tumors, and intradural spinal cord tumors. He will discus the contributions of co-morbidities and frailty on the management of patients with spinal tumors. He will also aim to give the audience a brief exposure to the surgical management of spinal oncology, and what is entailed to execute robust local control.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Join Maggie M. Hodges, MD, MPH, for a surgeon's perspective on the role of cancer risk reduction through bariatric surgery, while also exploring the optimal timing of bariatric surgery in patients with a personal history of cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Frances Collichio, MD, reviews the common and uncommon side effects of immune check point inhibitors. She also discusses the relatively new concept of delayed immune related events.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.25 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Dominique Higgins, MD, PhD, provides an overview of diagnostic criteria for primary CNS brain tumors, and the current approved and investigational treatments that are available and on the horizon.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Katherine Garman, MD, and Meira Epplein, PhD, will provide information on gastric cancer and important risk factors such as H. pylori infection. We will describe some of the racial disparities associated with gastric cancer in the US, highlighting those that are relevant for North Carolina. We will also discuss H. pylori as a modifiable risk factor and we will review current guidelines on H. pylori testing, treatment, eradication testing, and the growing problem of antibiotic resistance.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Daniel Richardson, MD, MA, MSc, will explore best practices to approach the care of older adults with leukemia. He will also discuss novel therapeutic options for patients with acute lymphoblastic and acute myeloid leukemia alongside practical considerations to approach shared decision-making.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.25 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Hung-Jui Tan, MD, MSHPM, will review recent practice-changing research and new management recommendations for patients with prostate, kidney, bladder, and testicular cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Mark Woodcock gives a broad overview of the multidisciplinary approaches for the treatment of soft tissue sarcomas in adults, and detailed updates in management with systemic therapies. Specific attention is paid to sarcoma sub-types which may warrant special considerations.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 ODS Category A
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Natalie Grover, MD, will review some of the recent advances in the treatment of lymphoma, including the incorporation of novel targeted agents in the frontline treatment of diffuse large B cell lymphoma and Hodgkin lymphoma, the use of CAR-T cell therapy in second-line treatment in diffuse large B cell lymphoma, and recently approved drugs by the FDA for lymphoma.

Pages